Biocon subsidiary, Biocon Biologics has partnered with the National Cancer Society of Malaysia (NCSM) to launch a Patient Assistance Program (PAP) that aims to make cancer treatment more affordable for underserved patients in Malaysia. ,
Through this collaboration, Biocon Biologics- a global biosimilars company, will supply key oncology biosimilars, including Trastuzumab, Pegfilgrastim, and Bevacizumab, to NCSM. The Malaysian not-for-profit organization will handle patient enrollment and medicine distribution as part of its community outreach and healthcare support services.
The partnership aims to address treatment delays
The program will begin by offering Trastuzumab to patients who are unable to start or continue treatment due to financial constraints. The initiative was formalized through a Memorandum of Understanding (MoU) signed during the National Cancer Congress Malaysia 2025, held in Kuala Lumpur.
“This partnership marks a meaningful step forward in expanding access to high-quality oncology biosimilars for cancer patients in need,” said Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics. “By combining our scientific expertise with NCSM’s strong patient support network, we aim to ease the treatment burden for underserved populations.”
Expanding Biocon’s presence in Malaysian healthcare
Biocon Biologics is already active in Malaysia’s healthcare landscape. It previously helped over 345,000 diabetes patients through affordable treatment programs. With this new focus on oncology, the company is strengthening its commitment to inclusive, patient-centric healthcare.
Share price of Biocon rebound after dip
Biocon Biologics, is a Bengaluru-based company and subsidiary of Biocon, operates in over 120 countries. The share price of Biocon has seen notable fluctuations over the past month. Although it has gained around 4.65 per cent during this period, the stock had dropped to nearly Rs 330 before recovering.
The company develops and delivers affordable biosimilars for chronic diseases such as cancer, diabetes, and autoimmune conditions. So far, it has launched nine biosimilars globally and is working on 20 more across various therapeutic areas.